科前生物
(688526)
| 流通市值：71.88亿 | | | 总市值：71.88亿 |
| 流通股本：4.66亿 | | | 总股本：4.66亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 245,188,828.52 | 941,923,862.86 | 665,506,663.22 | 400,510,475.63 |
| 营业收入 | 245,188,828.52 | 941,923,862.86 | 665,506,663.22 | 400,510,475.63 |
| 二、营业总成本 | 133,324,710.25 | 547,793,468.42 | 393,227,605.15 | 241,479,146.09 |
| 营业成本 | 83,667,726.68 | 341,394,102.64 | 239,543,620.7 | 147,241,803.17 |
| 税金及附加 | 1,624,952.64 | 6,175,244.01 | 4,425,630.06 | 2,639,821.27 |
| 销售费用 | 27,319,280.7 | 114,045,783.13 | 93,026,235.06 | 56,108,072.46 |
| 管理费用 | 14,372,200.88 | 61,639,233.33 | 41,088,599.54 | 25,394,130.7 |
| 研发费用 | 21,330,798.19 | 86,121,440.39 | 61,152,604.48 | 40,359,385.44 |
| 财务费用 | -14,990,248.84 | -61,582,335.08 | -46,009,084.69 | -30,264,066.95 |
| 其中:利息费用 | 75,256.86 | 4,769,834.14 | 4,553,324.05 | 3,345,757.16 |
| 其中:利息收入 | 15,099,461.19 | 66,557,040.92 | 50,740,386.7 | 33,776,797.01 |
| 加:公允价值变动收益 | 4,637,893.94 | 30,986,081.97 | 17,180,358.45 | 6,442,306.81 |
| 加:投资收益 | 1,485,275.25 | 6,616,220.42 | 11,262,998.83 | 3,688,044.98 |
| 资产处置收益 | - | 926,906.06 | 926,906.06 | 926,906.06 |
| 资产减值损失(新) | -4,320,266.79 | -16,080,317.97 | -17,299,862.03 | -9,697,299.89 |
| 信用减值损失(新) | 9,056,930.53 | -12,387,446.79 | -7,057,566.43 | -3,466,812.06 |
| 其他收益 | 2,949,688.73 | 34,655,817.28 | 20,216,362.37 | 16,671,873.89 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 125,673,639.93 | 438,847,655.41 | 297,508,255.32 | 173,596,349.33 |
| 加:营业外收入 | 47,370.4 | 167,637.96 | 93,582.98 | 3,434.5 |
| 减:营业外支出 | 225,959.33 | 882,440.48 | 790,205.91 | 669,951.73 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 125,495,051 | 438,132,852.89 | 296,811,632.39 | 172,929,832.1 |
| 减:所得税费用 | 17,708,778.25 | 56,643,206.58 | 36,804,185.17 | 20,693,684 |
| 六、净利润 | 107,786,272.75 | 381,489,646.31 | 260,007,447.22 | 152,236,148.1 |
| 持续经营净利润 | 107,786,272.75 | 381,489,646.31 | 260,007,447.22 | 152,236,148.1 |
| 归属于母公司股东的净利润 | 108,236,874.48 | 382,350,180.06 | 260,600,917.75 | 152,608,566.88 |
| 少数股东损益 | -450,601.73 | -860,533.75 | -593,470.53 | -372,418.78 |
| (一)基本每股收益 | 0.23 | 0.82 | 0.56 | 0.33 |
| (二)稀释每股收益 | 0.23 | 0.82 | 0.56 | 0.33 |
| 八、其他综合收益 | 15,356,455.6 | -42,473,821.86 | -7,555,091.9 | 4,375,869.32 |
| 归属于母公司股东的其他综合收益 | 15,356,455.6 | -42,473,821.86 | -7,555,091.9 | 4,375,869.32 |
| 九、综合收益总额 | 123,142,728.35 | 339,015,824.45 | 252,452,355.32 | 156,612,017.42 |
| 归属于母公司股东的综合收益总额 | 123,593,330.08 | 339,876,358.2 | 253,045,825.85 | 156,984,436.2 |
| 归属于少数股东的综合收益总额 | -450,601.73 | -860,533.75 | -593,470.53 | -372,418.78 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |